Venture Capitalists push FDA Reform on Capitol Hill
In a recent survey of venture capital firms, many say they are investing fewer dollars in biotechnology drugs and devices because of an unpredictable and risk adverse FDA. The companies took their case for FDA reform to Capitol Hill this week engaging Senators in the debate. From the Venture Capital Dispatch…
Venture capitalists are beginning to steer their investment dollars away from fledgling pharmaceutical and medical device companies, a phenomenon that will drive jobs and promising treatments overseas, according to a new survey of life sciences investors.
The chief reason, according to most of the 156 venture firms surveyed, is dysfunction at the Food and Drug Administration, an agency investors say is so unpredictable and risk-averse that young companies are now inclined to merely give up on trying to get on the market in the U.S. Read more…
Chris Centeno, MD
is a specialist in regenerative medicine and the new field of Interventional Orthopedics. Centeno pioneered orthopedic stem cell procedures in 2005 and is responsible for a large amount of the published research on stem cell use for orthopedic applications. View Profile
If you have questions or comments about this blog post, please email us at [email protected]
NOTE: This blog post provides general information to help the reader better understand regenerative medicine, musculoskeletal health, and related subjects. All content provided in this blog, website, or any linked materials, including text, graphics, images, patient profiles, outcomes, and information, are not intended and should not be considered or used as a substitute for medical advice, diagnosis, or treatment. Please always consult with a professional and certified healthcare provider to discuss if a treatment is right for you.
Get Blog Updates by Email
We do not sell, or share your information to third party vendors.
We will provide information to help you decide whether you want to schedule an evaluation with a Regenexx Physician.
Insurance typically covers evaluations and diagnostic testing (if recommended). Most insurance plans currently do not cover Regenexx Procedures.